#1 Clinical Trials Search in Europe

Study Comparing Gallium (68Ga) Gozetotide and Zirconium (89Zr) Girentuximab PET Scans for Detecting Tumors in Patients with Metastatic Renal Cell Carcinoma

1 1 1 1

What is this study about?

This clinical trial is focused on studying a type of kidney cancer known as clear cell renal cell carcinoma (ccRCC), which can spread to other parts of the body, a condition referred to as metastatic renal cell carcinoma. The study aims to compare two different imaging methods to see how well they can detect tumors in patients suspected of having this type of cancer. The two imaging methods being compared are 68Ga-gozetotide (PSMA) PET and 89Zr-DFO-girentuximab PET. These are special scans that help doctors see where the cancer might be in the body.

The purpose of the study is to explore and compare how effectively these two imaging methods can find tumors. Patients will receive both types of scans, and the results will be compared to see which method is better at detecting the cancer. The study will also look at how the cancer appears in these scans compared to a standard imaging method called computed tomography (CT), which uses X-rays to create detailed pictures of the inside of the body.

During the study, patients will undergo these imaging tests, and the results will be analyzed to determine the best way to detect tumors in this type of kidney cancer. The study will help doctors understand which imaging method provides the most accurate information about the presence and spread of the cancer, potentially leading to better diagnosis and treatment options for patients with metastatic renal cell carcinoma.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing the suspicion of metastatic clear cell renal cell carcinoma (ccRCC) based on a recent contrast-enhanced CT scan.

Eligibility requires that the CT scan be performed no more than four weeks prior to the PET scan. A biopsy may or may not have been conducted before joining the study.

2 first imaging session

The first imaging session involves the administration of gallium (68Ga) gozetotide via intravenous injection. This is a solution for injection used to perform a PET scan.

The purpose of this scan is to visually and semi-quantitatively assess tumor detection rates.

3 second imaging session

The second imaging session involves the administration of zirconium (89Zr) girentuximab via intravenous injection. This is also a solution for injection used for a PET scan.

This session aims to compare the tumor detection rates with those from the first imaging session.

4 data analysis

The data from both PET scans, along with the conventional contrast-enhanced CT, are analyzed to evaluate tumor detectability and detection rates.

The analysis includes a semi-quantitative assessment of the maximum standardized uptake value (SUVmax) in the primary tumor and metastases, as well as the tumor-to-background ratio.

Who Can Join the Study?

  • Must be 18 years or older.
  • There should be a suspicion of metastatic ccRCC (a type of kidney cancer that has spread to other parts of the body) based on a contrast-enhanced CT scan. This scan should be done no more than 4 weeks before the PET scan.
  • The diagnosis of the cancer may or may not be confirmed by a biopsy (a small sample of tissue taken from the body to examine it more closely) before joining the study.
  • The primary tumor (the original cancer site) may or may not still be present in the body.
  • Both male and female participants are eligible.
  • Participants should not belong to a vulnerable population (groups that may need special protection or care).

Who Cannot Join the Study?

  • Patients who do not have metastatic renal cell carcinoma. This is a type of kidney cancer that has spread to other parts of the body.
  • Patients who are not within the specified age range. The study is open to certain age groups, so if you are outside this range, you cannot participate.
  • Patients who are part of a vulnerable population. This means people who might need special protection or care, such as those with certain disabilities or conditions.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Stichting Radboud University Medical Center Nijmegen The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Recruiting
01.01.2025

Trial locations

Investigated drugs:

68Ga-gozetotide (PSMA) is a type of imaging agent used in PET scans to help detect tumors. It targets a specific protein found on the surface of certain cancer cells, making it easier for doctors to see these cells during imaging tests. This helps in identifying the presence and spread of cancer in the body.

89Zr-girentuximab is another imaging agent used in PET scans. It binds to a different protein that is often present in kidney cancer cells. By attaching to these cells, it allows doctors to visualize the cancer more clearly during imaging, aiding in the diagnosis and monitoring of the disease.

Investigated diseases:

Metastatic Renal Cell Carcinoma – This is a type of kidney cancer that has spread beyond the kidney to other parts of the body. It originates in the renal cortex, where the cells begin to grow uncontrollably, forming a tumor. As the disease progresses, cancer cells can travel through the bloodstream or lymphatic system to distant organs, such as the lungs, bones, or liver. The spread of cancer cells to other parts of the body is known as metastasis. This condition can lead to various symptoms depending on the organs affected, such as pain, fatigue, or weight loss. The progression of the disease can vary, with some patients experiencing rapid spread while others may have a slower progression.

Trial ID:
2024-514181-39-00
Protocol code:
115747
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Axitinib and Pembrolizumab for Patients with Advanced or Metastatic Papillary Renal Cell Carcinoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France